mRNA-CR-04
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 28, 2025
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
(clinicaltrials.gov)
- P1 | N=114 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | N=72 ➔ 114
Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
February 09, 2024
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
(clinicaltrials.gov)
- P1 | N=72 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 21, 2023
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 02, 2023
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
(clinicaltrials.gov)
- P1 | N=72 | Not yet recruiting | Sponsor: GlaxoSmithKline
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1